Teva Pharmaceuticals (NYSE:TEVA) has launched its Qvar RediHaler inhalation aerosol in the U.S., marking the first time a breath-actuated inhaled corticosteroid is available for asthma patients as a prophylactic therapy.
In contrast to traditional metered-dose inhalers, Teva’s Qvar RediHaler sends medication into the user’s lungs as they inhale. This feature eliminates the need for hand-breath coordination, according to Teva.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva launches breath-activated asthma aerosol in U.S. appeared first on MassDevice.
from MassDevice http://ift.tt/2BoX2PW
Cap comentari:
Publica un comentari a l'entrada